{"id":"loperamide-seldiar","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loperamide binds to mu-opioid receptors in the enteric nervous system, which decreases peristalsis and increases absorption of water and electrolytes in the intestines. It has minimal systemic absorption and does not cross the blood-brain barrier at therapeutic doses, making it a peripherally selective opioid agonist with low abuse potential compared to systemic opioids.","oneSentence":"Loperamide is a mu-opioid receptor agonist that slows intestinal motility and reduces fluid secretion to decrease diarrhea.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:47.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute diarrhea"},{"name":"Chronic diarrhea"},{"name":"Traveler's diarrhea"}]},"trialDetails":[{"nctId":"NCT03705442","phase":"PHASE2","title":"Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Marin Golčić","startDate":"2018-02-09","conditions":"Colorectal Cancer Metastatic","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20200414","type":"SUPPL","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20221122","type":"SUPPL","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20200414","type":"SUPPL","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20200414","type":"SUPPL","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20060906","type":"ORIG","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20200414","type":"SUPPL","sponsor":"SUN PHARM INDS LTD","applicationNumber":"ANDA077500"},{"date":"20151130","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA091292"},{"date":"20151130","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA091292"},{"date":"20211213","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA091292"},{"date":"20211213","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA091292"},{"date":"20110520","type":"ORIG","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA091292"},{"date":"20211006","type":"ORIG","sponsor":"EDENBRIDGE PHARMS","applicationNumber":"ANDA215001"},{"date":"20180905","type":"ORIG","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA209837"},{"date":"20191203","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA209837"},{"date":"20210709","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA209837"},{"date":"20230905","type":"ORIG","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA218122"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["loperamide (\"Seldiar\"), Standard antidiarrhoeal drug"],"phase":"marketed","status":"active","brandName":"loperamide (\"Seldiar\")","genericName":"loperamide (\"Seldiar\")","companyName":"Marin Golčić","companyId":"marin-gol-i","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loperamide is a mu-opioid receptor agonist that slows intestinal motility and reduces fluid secretion to decrease diarrhea. Used for Acute diarrhea, Chronic diarrhea, Traveler's diarrhea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}